Palatin stock minimally aroused by sexual dysfunction data for bremelanotide
This article was originally published in Scrip
Executive Summary
Palatin Technologies may be able to start a Phase III clinical trial for its female sexual dysfunction (FSD) drug bremelanotide by the fourth quarter of 2013 based on statistically significant Phase IIb results.